KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Latest Data & Signals Issued

Signal Type Signal Value Data
Score -2.787 7 days ( 3.03 % )
Last Price $1.28 8.47 %
High/ Low $1.19 - $1.31 3.36%
Chg 7 Days -3.03 % $1.32 $1.28
Chg 30 Days -28.09 % $1.78 $1.28
Chg 12 mos 81.12 % $0.707 $1.28
Trend - 3 mos 118.86 % Width: 78.75 %
Trend - 12 mos 54.52 % Width: 214.01 %
Pred. range - 3 mos $2.62 - $4.69 104.97 % - 266.38 %
Pred. range - 12 mos $0.94 - $2.96 -26.27 % - 131.51 %
Short MA avg 3 mos Buy Apr 25, 2024 - 2 days
Long MA avg 3 mos Sell Apr 17, 2024 - 8 days
Short/Long MA avg 3 mos Sell Apr 23, 2024 - 4 days
Short MA avg 12 mos Sell Apr 16, 2024 - 9 days
Long MA avg 12 mos Buy Dec 21, 2023 - 87 days
Short/Long MA avg 12 mos Buy Dec 28, 2023 - 83 days
Pivot Short Sell Apr 08, 2024 - 15 days
Bollinger Buy Feb 12, 2024 - 53 days
MACD Sell No Dates Stored For This Signal

Signals Effectiveness

Backtesting is not only a way to check stock signal accuracy, but also a tool to continually improvement. Data can be used for self adjustment as each stock has an individual behavior.

Accuracy and return is not the same. A stock signal may provide low statistical accuracy, but the signals may prove high return in average.

Sharp market dips or fundamental changes (earning reports, news updates etc), may force a short term reaction and disturb the signals (Signals may jump quickly from buy to sell, just to return to buy).

Stock Score

Buy Signals
Sell Signals

Bollinger Bands

Buy Signals
Sell Signals

MACD

Buy Signals
Sell Signals

Moving Average (7d)

Buy Signals
Sell Signals
Click to get the best stock tips daily for free!

About Ocugen Inc

Ocugen Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related ... OCGN Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT